Rimegepant

Evidence-based neurology checklist on rimegepant: Dose The dose is 75mg orally disintegrating table It is placed on or under the tongue and swallowed without liquid The maximum dose is 75mg in 24 hours Indication Contraindications Side effects

Dose

  • The dose is 75mg orally disintegrating table
  • It is placed on or under the tongue and swallowed without liquid
  • The maximum dose is 75mg in 24 hours

Indication

Contraindications

Side effects

References

  1. Scott LJ. Rimegepant: first approval. Drugs 2020; 80:741-746.
  2. Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet 2019; 394:737-745.
  3. Lipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med 2019; 381:142-149.
  4. Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet 2021; 397:51-60.

Related checklists

Loading...